This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network

Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI) (, announced today that President and Chief Executive Officer Bassam Damaj, Ph.D., has been interviewed by, a New York-based financial network ( The interview is currently available at or directly at

Apricus Bio announced on November 15, 2010 that Health Canada has granted marketing approval for Vitaros ®, the Company’s proprietary, topically applied, on-demand treatment for erectile dysfunction. In the interview at, Dr. Damaj explained that Apricus Bio decided to research, develop, and seek approval for Vitaros for several reasons, including addressing the unmet medical need for a patient-friendly, on-demand topical treatment suitable for patients with erectile dysfunction of different severity. Dr. Damaj said that now, with Vitaros, patients with cardiac disease, hypertension, diabetes, and patients who are obese or who are not successful or contraindicated for currently available oral erectile dysfunction drugs, will have a fast-acting and non-painful alternative.

Apricus Bio developed the Vitaros cream by incorporating its proprietary NexACT ® permeation enhancer technology with alprostadil, a well-recognized vasodilator and treatment for erectile dysfunction that is currently marketed as an injectable product or an intraurethral insert product. The NexACT delivery technology has been clinically validated by Health Canada’s approval and the Vitaros cream treatment will be available to patients in Canada. Apricus Bio also intends to use the Canadian approval as the basis for seeking registration of the product for potential marketing in more than 100 international markets.

In the interview, Dr. Damaj noted that there is currently a $3 billion market worldwide for erectile dysfunction treatments, with oral medication dominating the marketplace. Some urologists have said that a prescribed topical erectile dysfunction treatment has the potential to capture up to 20-30 percent of their patients, once approval is granted.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs